Tag: Akari Therapeutics

FDA, Regulations

FDA Agrees to Use of New Manufacturing Process for Nomacopan in Clinical Studies

January 19, 2022

Via: Contract Pharma

Akari Therapeutics, Plc, a late-stage biopharmaceutical company focused on therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, has announced that the U.S. Food and Drug Administration ( FDA ) has agreed, […]